iShares MSCI Pacific ex J... (EPP)
44.06
0.54 (1.24%)
At close: Jan 15, 2025, 11:16 AM
undefined% (undefined)
| Bid | 44.06 |
| Market Cap | 2.34B |
| AUM | - |
| NAV | - |
| EPS (ttm) | 2.41 |
| PE Ratio (ttm) | 18.27 |
| Shares Out | 53.10M |
| Inception Date | Invalid Date |
| Ask | 44.07 |
| Volume | 82.55K |
| Open | 44.21 |
| Previous Close | 43.52 |
| Day's Range | 44.05 - 44.23 |
| 52-Week Range | 40.22 - 49.29 |
| Holdings | - |
| Expense Ratio | undefined% |
About EPP
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index consists of stocks from the following four countries or regions: Australia, Hong Kong, New Zealand and Singapore. The underlying index include large- and mid-capitalization companies and may change over time. The fund is non-diversified.
Asset Class Equity
Ticker Symbol EPP
Inception Date Oct 26, 2001
Provider Blackrock
Website Fund Home Page
Top Sectors
| Sector | Weight % |
|---|---|
| Financial Services | 41.73% |
| Basic Materials | 12.83% |
| Real Estate | 8.71% |
| Healthcare | 7.58% |
| Industrials | 7.51% |
Top Holdings 28.36% of assets
| Company | Portfolio |
|---|---|
CBA.AX Commonwealth Bank Of... | 8.78% |
BHP.SW Bhp Group Ltd | 6.90% |
CSL.AX Csl Ltd | 4.66% |
1299.HK Aia Group Ltd | 4.09% |
NAB.AX National Australia B... | 3.93% |
Dividends Dividend Yield 4.43%
| Ex-Dividend | Payment Date | Amount |
|---|---|---|
| Dec 17, 2024 | Dec 20, 2024 | $0.97 |
| Jun 11, 2024 | Jun 17, 2024 | $0.70 |
| Dec 20, 2023 | Dec 27, 2023 | $0.97 |
| Jun 7, 2023 | Jun 13, 2023 | $0.81 |
| Dec 13, 2022 | Dec 19, 2022 | $0.71 |
7 months ago · seekingalpha.com
Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 ProgressDisc Medicine, Inc. released positive results from the phase 2 AURORA study, using bitopertin for the treatment of patients with EPP and XLP. Potential FDA feedback to initiate a pivotal study using b...